103 serum samples from 82 intravenous drug abusers, all of them seropositive for antibody against HIV: 12 were asymptomatic, 54 had the AIDS related complex, and 16 had AIDS. The samples were obtained between July 1984 and December 1986 and repeated samples were taken in 18 patients after a time interval of more than six months.
Twelve samples were antigen positive: seven out of 16 samples from patients with AIDS (44%) and four out of 75 samples from patients with AIDS related complex (6%) (p<005). HIV antigen was not detected in any of the 14 samples from asymptomatic patients.
Study of specific antibody against the core protein (anti-p24) was performed in 12 antibody positive samples with a competitive enzyme linked immunosorbent assay (ELISA) (HTLV-III Envacore, Abbott) and showed a lack ofanti-p24 in four out of 12 samples from four patients with AIDS; only one of four HIV antigen positive patients with AIDS related complex showed absence of anti-p24.
Eight patients with AIDS had oesophageal candidiasis as their sole opportunistic infection; HIV antigen was not recognised in any of them. Nevertheless, antigenaemia was present in seven out of eight patients who presented with opportunistic infections other than oesophageal candidiasis. Even though studies are required in a larger number of patients, this different incidence of HIV antigen among the patients with AIDS who presented with only oesophageal candidiasis could suggest a better prognosis for them. Repeat prescribing of non-steroidal anti-inflammatory drugs SIR,-In October 1986 we carried out an audit of our prescribing of non-steroidal anti-inflammatory drugs by examining a range of data similar to those of Dr K Steele and others (17 October, p 962) and relating to all patients receiving these drugs in our practice over one month (list size 13500, total doctor-patient contacts for the period 3154).
We examined the records of all patients who received non-steroidal anti-inflammatory drugs during the study period, taking care to include all those who received prescriptions at home visits or prescriptions written by hand without the patient being seen as well as those issued by our computerised repeat prescribing system and at face to face consultations. We found 22 patients who received a repeat prescription for non-steroidal agents other than via the computerised system, including seven who had had prescriptions for these drugs renewed at a home visit.
In the month of the study we issued 108 prescriptions for these agents to 3-42% of all doctor-patient contacts and at 3-1% of all face to face contacts. Of these 52 were issued for the first time in the month of the study and 56 were reissues. Like Dr Steele and others we found that more prescriptions were issued to women and to people over 65 years, though the differences between sexes and age groups were less pronounced. Thus 64 of 108 prescriptions for these drugs were issued to women and of the 56 which were reissues 24 were to people aged over 65.
The indications for long term use-that is, reissuing of a further prescription for a nonsteroidal anti-inflammatory drug-were similar to those found in the Belfast study: osteoarthrosis 28; rheumatoid arthritis 8; soft tissue problems 11. The small differences from the authors' finding may well be accounted for by our different definition of long term treatment.
Three drugs-ibuprofen, naproxen, and indomethacin-accounted for 90 Paediatric Oncology, lists the costs of cytotoxic chemotherapy in three hospitals before and after the appointment of medical oncologists. For one of these hospitals the costs given refer to one drug only. Many factors can have a bearing on drug expenditure, including loss of patents and commercial sponsorship of clinical research. No analysis is given which could lead to the conclusion that the change in expenditure was wholly or partly due to a change in prescribing habits, and no information is given on changes in chemotherapy costs at other institutions.
The credibility of this document is further undermined by the robust implications that skill in cytotoxic chemotherapy is the prerogative solely of medical oncologists and that no patients with metastatic germ cell tumours and only 5% of
